HR 4299
Protecting Patient Access to Cancer and Complex Therapies Act
Jurisdiction
US Congress
Session
119th Congress (2025-2026)
Last updated at
Jun 14, 2026, 1:34 AM
Take action
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Bill overview
This bill, the Protecting Patient Access to Cancer and Complex Therapies Act, aims to lower the cost of certain expensive medications for Medicare beneficiaries. It establishes a system where drug manufacturers must provide rebates to the government for selected drugs (specifically cancer and complex therapies) if the payment amount (based on a ‘maximum fair price’ negotiation) exceeds a calculated amount. The bill mandates that manufacturers report detailed information to the government about drug sales and rebates, and adjusts Medicare cost-sharing to reflect these rebates, ultimately reducing out-of-pocket expenses for patients.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Cosponsors
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.